Bluesky Project
Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022
All Resources
Our resource hub to discover reports, policy papers and other forms of informative content
Filter by
Addendum to IMC Submission on Drugs for Rare Diseases
Innovative Medicines Canada provides Health Canada with additional input regarding IMC’s March 2021 consultation submission on drugs for rare diseases.
Towards a Value-based and Pan-Canadian Rare Disease Strategy
IMC proposes a value-based, pan-Canadian rare disease strategy, built in collaboration with provinces, patients, clinicians and industry to fill gaps and meet specific needs.
Time to Listing: Canada’s public plans cover fewer new medicines and take longer than most OECD countries to approve them
Public plans in Canada cover fewer medicines than in other OECD20 countries and take longer to be approved. For rare-disease medicines, this gap is even larger.
